Cardiol Therapeutics Inc. reported achieving a 50% patient enrollment milestone in the pivotal Phase III MAVERIC trial for recurrent pericarditis, as detailed in their filing dated January 13, 2026. This is a positive development for the company's ongoing clinical research.